Candel Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
CADL$8.75+8.8%Stored close · as of Nov 6, 2026
Contents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Candel Therapeutics, Inc. | ||
| Date: May 14, 2024 | By: | /s/ Paul Peter Tak |
|---|---|---|
| Paul Peter Tak | ||
| President and Chief Executive Officer | ||
| Date: May 14, 2024 | By: | /s/ Charles Schoch |
| Charles Schoch | ||
| Interim Chief Financial Officer(Principal financial officer and principal accounting officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.